文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

长期非恶性疼痛患者处方阿片类药物减量(TOPIO):疗效及对疼痛、疼痛认知与生活质量影响的研究方案

Tapering of prescribed opioids in patients with long-term non-malignant pain (TOPIO)-efficacy and effects on pain, pain cognitions, and quality of life: a study protocol for a randomized controlled clinical trial with a 12-month follow-up.
PubMed 文献 · Trials · 2021-07-28

本研究为随机对照试验方案,计划纳入140例长期非恶性疼痛患者,随机分为立即减量组与4个月后减量的常规照护对照组,随访12个月。主要评估结构化干预能否稳定减少阿片 consumption,并观察减量对疼痛、疼痛认知、身心健康、生活质量及功能的影响。

要点

  • 结构化阿片减量干预可能稳定减少长期非恶性疼痛患者的阿片消耗。
  • 研究同时评估减量对疼痛、疼痛认知、生活质量及功能的多维影响。
  • 采用瑞典药物登记数据计算吗啡等效日剂量,并结合多个量表评估。

核心结论

  • 需通过随机对照试验评估结构化阿片减量干预能否稳定减少长期非恶性疼痛患者的阿片消耗及其多维影响。

研究设计与样本

  • 随机对照试验,样本量设为140例,来自长期非恶性疼痛人群。
  • 参与者随机分为立即开始减量组或4个月后开始减量的常规照护对照组,随访12个月。

关键数值与推荐

  • 样本量设定为140例,基于功效和脱落率估算。
  • 在基线、干预开始后4个月和12个月计算个体平均日阿片剂量(吗啡等效剂量)。
  • 同时间点填写NPRS、TSK、PCS、CPAQ-8、HADS和RAND-36问卷。
  • 基线和随访时进行阿片使用障碍的临床评估。

临床怎么用

  • 研究结果可能为长期非恶性疼痛患者的阿片减量实践提供证据支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Opioids are still widely prescribed to long-term pain patients although they are no longer recommended for long-term treatments due to poor evidence for long-term efficacy, risks of serious side effects, and the possibility of inducing opioid hyperalgesia. In a Cochrane study from 2017, the authors identified an urgent need for more randomized controlled trials investigating the efficiency and effects of opioid tapering. The study aimed to assess (1) the efficiency of a structured intervention in causing stable reductions of opioid consumption in a population with long-term non-malignant pain and (2) effects on pain, pain cognitions, physical and mental health, quality of life, and functioning in response to opioid tapering. METHODS: The study is a randomized controlled trial. The sample size was set to a total of 140 individuals after estimation of power and dropout. Participants will be recruited from a population with long-term non-malignant pain who will be randomly allocated to (1) the start of tapering immediately or (2) the control group who return to usual care and will commence tapering of opioids 4 months later. A 12-month follow-up is included. When all follow-ups are closed, data from the Swedish drug register of the National Board of Health and Welfare will be collected and individual mean daily opioid dose in morphine equivalents will be calculated at three time points: baseline, 4 months, and 12 months after the start of the intervention. At the same time points, participants fill out the following questionnaires: Numeric Pain Rating Scale (NPRS), Tampa Scale of Kinesiophobia (TSK), Pain Catastrophizing Scale (PCS), Chronic Pain Acceptance Questionnaire (CPAQ-8), Hospital Anxiety and Depression Scale (HADS), and RAND-36. At baseline and follow-up, a clinical assessment of opioid use disorder is performed. DISCUSSION: A better understanding of the efficiency and effects of opioid tapering could possibly facilitate attempts to taper opioid treatments, which might prove beneficial for both the individual and society. TRIAL REGISTRATION: ClinicalTrials.gov NCT03485430 . Retrospectively registered on 26 March 2018, first release date. "Tapering of Long-term Opioid Therapy in Chronic Pain Population. RCT with 12 Months Follow up (TOPIO)." First patient in trial 22 March 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Henrik G, Patrik M, Anders H, et al. Tapering of prescribed opioids in patients with long-term non-malignant pain (TOPIO)-efficacy and effects on pain, pain cognitions, and quality of life: a study protocol for a randomized controlled clinical trial with a 12-month follow-up. Trials. 2021. PMID: 34321058. doi:10.1186/s13063-021-05449-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。